Navigation Links
TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
Date:6/4/2008

LA JOLLA, Calif., June 4 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced it has initiated a clinical trial to evaluate the analgesic effect of NGX426, the oral prodrug of its lead product candidate, tezampanel.

The randomized, double-blind, placebo-controlled Phase I trial will enroll 18 healthy volunteers at a single center in the United States. The trial is designed to evaluate the compound's safety and tolerability and to assess the time of onset, magnitude and duration of its analgesic effect. Specifically, the study will evaluate the effect of NGX426 on hyperalgesia, an abnormally increased pain state, and allodynia, pain resulting from normally non-painful stimuli to the skin, induced by intradermal injections of capsaicin. The primary endpoint is subject self-report of spontaneous pain following the injection of capsaicin.

"We believe there is a substantial commercial opportunity for NGX426 as a novel, oral analgesic," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics. "Data we have obtained in our ongoing Phase I maximum tolerated dose study demonstrate that the drug is well-tolerated at single doses up to and including 210 mg and that NGX426 is rapidly converted to tezampanel. Moreover, this capsaicin study, if successful, will enable us to further take advantage of the versatility of NGX426 and the overall tezampanel franchise."

Subjects in the trial, which involves the recognized and validated capsaicin-induced pain model, will receive single doses of 90 mg and 150 mg of NGX426 versus placebo in a three-way crossover design.

Tezampanel is the first AMPA/kainate-type glutamate receptor antagonist to be studied in clinical t
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
2. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
3. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
4. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
5. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
9. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
10. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
11. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...TON, Mass., Nov. 6 DUSA ... dermatology company that is developing and market... other products focused on patients with common sk... and Chief Executive Officer, will present a corpo... Summit 2009 on Tuesday, November 10, 2009 at 10:0...
(Date:11/6/2009)...A, Fla., Nov. 6 Roper I...t it has signed a definitive agreement to acquire ...medical devices. The Verathon Board of Directors ...bject to customary regulatory approvals and closin... parties expect the closing to be completed in ear...
(Date:11/6/2009)...ON, Mass., Nov. 6 Facet Solutions,...the assets of Archus Orthopedics. The acquisition ...ct offerings, intellectual property and clinical e...is a win for patients suffering from lumbar spinal...; CEO, Geoff Pardo. "This consolidation further s...
Breaking Medicine Technology:Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 2Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 3Facet Solutions Acquires Archus Orthopedics 2Chemobrain the flip side of surviving cancer 57499 1Chemobrain the flip side of surviving cancer 57499 2The wonders of wine 9962 1The wonders of wine 9962 2The wonders of wine 9962 3InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture 9957 1InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture 9957 2
...-A team of researchers at the,National Cancer Inst...alth (NIH), has uncovered a set of genes that are ...e blood vessels that feed,tumors in mice and human...important new potential targets for novel drugs th...y without affecting,the blood vessels of healthy t...
...-Jun 12, 2007 - Inspire,Pharmaceuticals, Inc. (NAS...laborators related to Inspire will present,informa...of,Allergology and Clinical Immunology (EAACI) bei... the 30th European Cystic Fibrosis,Society (ECFS) ...urkey., The EAACI Congress includes two presentati...
Other Medicine Technology:NCI Researchers Discover Genes That Are Turned on at High Levels in,Tumor-associated Blood Vessels of Mice and Humans 2NCI Researchers Discover Genes That Are Turned on at High Levels in,Tumor-associated Blood Vessels of Mice and Humans 3Inspire Announces Presentations at Two European Scientific,Conferences 2Inspire Announces Presentations at Two European Scientific,Conferences 3
(Date:11/9/2009)...ural Nutrition announced today the acquisition of ...owned subsidiary of Natural Nutrition. Natural Nu...and the company will focus its efforts on the busi...veloping mobile application market places througho...ocused on multi platform apps designed to run on d...
(Date:11/9/2009)...mber 10th, at 5:30 pm CST, Veronica Garza of MD An...herapy Options for Mesothelioma patients. Her lect... the mesocare.org website. , ...sothelioma lecture on Tuesday November 10th, 2009...e by Veronica Garza of MD Anderson Medical Center ...
(Date:11/9/2009)...ig are collaborating to provide Davis Applied Tech...ines. The equipment will be used to provide stude...n-architecture THINC control. Grand Opening Janua...te, NC (PRWEB) November 9, 2009 -- Okuma America C...utor Hartwig, Inc. will provide machine tool equip...
(Date:11/9/2009)... HUYA Bioscience International, a leader in global...announced a strategic partnership with the School ...a. The agreement is another in a series of collabo...ding research and development institutions to enab...rcialization of novel biopharmaceutical product op...
(Date:11/8/2009)...wswire/ -- Today, the nation Mayors commended the ...rdable Health Care for America Act, a historic pie...ing America,s healthcare system. ,, In June, at...vidence (RI), mayors from across the nation unanim...of reducing the long-term growth of health care co...
Breaking Medicine News(10 mins):Health News:Okuma America Corporation & Hartwig, Inc. to Provide Machines to Davis Applied Technology College for Machine Tool Technology Program 2Health News:HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China 2Health News:The Nation's Mayors Commend House Passage of Health Reform Bill 2
..." (p. 36). Health Reporter,Jeneen Interlandi exami...h,that are showing how the brain functions in addi...determine that addiction is a legitimate,illness a...disease. In essence, an addict,s brain is,malfunct...
...ating the Disease as Chronic, ...erstanding Biology of Addiction ,and That is Final...ling, to ,Legitimate Illness, S...ginning to see treatments that target the underlyi...
...study finds , , SATURDAY, Feb. 23 (Health...e barriers to health care may be among the reasons...an in Europe, a new study suggests. , Researchers ...likely to suffer a stroke than European men, and A...
...es,Inc. (NYSE: AHS ), the nation,s largest health...C. Francis, co-founder and Chairman of AMN,Healthc...ompany,s annual,shareholder meeting on April 9, 20...been a director of AMN Healthcare since its incept...
...back and neck surgeon at Rush University Medical C...ents who underwent surgery for spinal stenosis sho...outcomes than did patients who were treated nonsur...n the spine through which nerves pass, and it can ...
...istory of abuse, family problems , , FRIDA...he middle-aged male sex offender posing online as ...ne meetings where they can be abducted and raped i...wanting sex, and use instant messaging, e-mail and...
Other Medicine News:Health News:NEWSWEEK: Media Lead Sheet/March 3, 2008 Issue (on newsstands Monday, February 25) 2Health News:NEWSWEEK: Media Lead Sheet/March 3, 2008 Issue (on newsstands Monday, February 25) 3Health News:NEWSWEEK: Media Lead Sheet/March 3, 2008 Issue (on newsstands Monday, February 25) 4Health News:NEWSWEEK: Media Lead Sheet/March 3, 2008 Issue (on newsstands Monday, February 25) 5Health News:NEWSWEEK Cover: The Hunt for an Addiction Vaccine 2Health News:NEWSWEEK Cover: The Hunt for an Addiction Vaccine 3Health News:NEWSWEEK Cover: The Hunt for an Addiction Vaccine 4Health News:More Risk Factors, Less Access to Care Behind Higher Stroke Rates in U.S. 2Health News:AMN Healthcare Chairman Devotes Full Attention to Mayoral Race 2Health News:AMN Healthcare Chairman Devotes Full Attention to Mayoral Race 3Health News:Most Internet Sex Offenders Target Teens, Not Kids 2Health News:Most Internet Sex Offenders Target Teens, Not Kids 3
Spinal Instruments
...e been designed to work in conjunction with the Sy...lusively through LifeNet. Each I/C Graft Chamber i...ellous chips and demineralized allograft bone part...er possesses both osteoinductive and osteoconducti...
...nsive base of experience and knowledge in the use ...logous platelets are mixed with calcified thrombin...olved in coagulation take place. Secreted from the...onin, fibronectin, adenosine diphosphate, thrombox...
Leica D2D V3
Medicine Products: